EUROPE, U.S., AND INDIA LIQUID BIOPSY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The Europe, U.S., and India liquid biopsy market is estimated to be valued at USD 169.2 Mn in 2026 and is expected to reach USD 535.2 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 17.9% from 2026 to 2033. The Europe, U.S., and India liquid biopsy market is expected to grow at a fast pace due to the increasing global burden of cancer, increasing demand for less invasive diagnostic technologies, and increasing adoption of precision oncology. Liquid biopsy has become an important tool for early detection of cancer, comprehensive genomic profiling, therapy selection, and treatment monitoring, offering a faster and less invasive alternative to conventional tissue biopsy.

Additionally, the market is driven by the continuous advancements in next generation sequencing (NGS), biomarker discovery and companion diagnostics, along with positive regulatory approvals and increasing reimbursement support in developed countries. Rising investments in oncology research, increasing clinical adoption in hospitals and diagnostic laboratories, and rapid expansion of molecular diagnostics infrastructure in India are expected to further propel the market growth.

Market Dynamics

The Europe, U.S., and India liquid biopsy market is primarily driven by the increasing prevalence of cancer, rising need of early and minimally invasive cancer diagnostics and growing adoption of precision medicine. Development in next-generation sequencing (NGS), companion diagnostics and biomarker analysis, along with favorable regulatory approvals and increasing clinical applications in oncology, are boosting the adoption of liquid biopsy technologies across the region.

However, a number of constraints are present in the market, such as high cost of liquid biopsy tests, limited reimbursement in certain clinical scenarios, and the need for extensive clinical validation and standardized testing protocols. Nevertheless, rising adoption of multi-cancer early detection (MCED) tests, expanding applications in minimal residual disease (MRD) monitoring and therapy response assessment, and increasing investments in molecular diagnostics infrastructure are expected to create significant growth opportunities over the forecast period.

Key Features of the Study

• This report provides in-depth analysis of the Europe, U.S., and India liquid biopsy market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Europe, U.S., and India liquid biopsy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Exact Sciences Corporation, Bio-Rad Laboratories, Inc., Natera, Inc., Myriad Genetics, Inc., and Menarini Silicon Biosystems S.p.A
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Europe, U.S., and India liquid biopsy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe, U.S., and India liquid biopsy market

Market Segmentation

• Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Assay/Kits
  • Instruments
  • Services and Software
  • Accessories and Consumables
• Biomarker Type Insights (Revenue, USD Mn, 2021 - 2033)
  • CtDNA
  • CTCs
  • Extracellular Vesicles (EVS)
  • Others
• Disease Indication Insights (Revenue, USD Mn, 2021 - 2033)
  • Lung Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Skin Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Liver Cancer
  • Others
• Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Detection/Screening
  • Therapy Selection
  • Treatment Monitoring
• End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals
  • Cancer Institutes
  • Academic and Research Institutes
  • Diagnostic Centers/Laboratories
  • Others
• Key Players Insights
  • Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Exact Sciences Corporation
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Myriad Genetics, Inc.
  • Menarini Silicon Biosystems S.p.A